The Fifth Waigaoqiao Medical and Health Cooperation Forum was held at Waigaoqiao Life Science Park on December 6. The forum, themed "new opportunities for expanding openness in the medical field," focused on new industry projects, open initiatives, and development opportunities.
At the event, Shanghai Clinical Innovation and Transformation Research Institute, Ortho-Clinical Diagnostics Trading (China) Co Ltd, Nanjing Immunophage Biopharmaceutical Technology Co Ltd and Emedlo (Shanghai) Pharmaceutical Technology Co Ltd signed cooperation agreements with Waigaoqiao Group's Biopharmaceutical Company, Xin Development Company, and Gaoyue Life Sciences Group.
The Waigaoqiao Data Asset Service Package was launched at the event, operated by Waigaoqiao Biopharmaceutical Company. It aims to accelerate companies' digital transformation through comprehensive services, including data resource inventory, data product processing, data asset management, and data asset listing.
In 2023, the biopharmaceutical industry in the Pudong New Area accounted for over 40 percent of Shanghai's total, gathering 15 percent of the nation's Class I new drugs and 10 percent of innovative medical devices. The bonded area's biopharmaceutical industry achieved an operating income of 306 billion yuan (US$42.09 billion), a 7.3 percent increase from the previous year, accounting for about one-third of Shanghai's total.
Additionally, the import value of medical instruments and devices reached 41.7 billion yuan, a 7.7 percent increase from the previous year, accounting for 43.0 percent of the national import value of similar goods. The import value of pharmaceuticals was 96.3 billion yuan, a 15.6 percent increase, accounting for 26.4 percent of the national import value of similar goods.
